



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES, AND DATA MANAGERS

FROM: NRG-DT001 Study Chair

A handwritten signature in blue ink that reads "Meng Welliver".

Meng Welliver, MD, PhD

DATE: September 15, 2020

RE: PROTOCOL NRG-DT001 – Cohort A: Reopening to Accrual to Dose Level 3 (Expansion Cohort)

Cohort A Reopening to Accrual to Dose Level 3 (Expansion Cohort)

Cohort A (extremity/body wall) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” is reopened to accrual to dose level 3 effective immediately. Per protocol-specified dose limiting toxicity analysis, cohort A dose level 3 is considered safe to continue to the expansion cohort.

Cohort A will remain open to accrual until 5 additional wild-type p53 patients have been enrolled to dose level 3. A broadcast with more details regarding accrual closure will be sent when the target accrual has been reached.

Note: Cohort B (abdomen/pelvis/retroperitoneum) remains open to accrual to dose level 2.

Please distribute this information to the appropriate personnel.